

CITATION REPORT

List of articles citing

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

DOI: 10.1038/sj.leu.2405062
Leukemia, 2008, 22, 414-23.

Source: <https://exaly.com/paper-pdf/43666127/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
735	TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA. 46-63		
734	Dilantin in the treatment of lightning pains. 1961 , 11, 257-8		8
733	The Uses of Memory. 2002 , 8, 113-129		10
732	Thrombophilia and cancer. 2008 , 36, 131-6		25
731	The place of thalidomide in the treatment of multiple myeloma. 2008 , 1, 205-214		
730	Lenalidomide: towards a new standard in the optimal management of multiple myeloma. 2008 , 32, S20-S24		
729	Current awareness: Pharmacoepidemiology and drug safety. 2008 , 17, i-xvi		
728	Frontline treatment of multiple myeloma in elderly patients. 2008 , 22, 303-9		9
727	A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2008 , 81, 247-52	3.8	63
726	Practical considerations for multiple myeloma: an overview of recent data and current options. 2008 , 8 Suppl 4, S144-8		1
725	Tailored thromboprophylaxis for patients with multiple myeloma treated by IMiDs. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1644-5	1.9	6
724	Aspirin as thromboprophylaxis in myeloma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1646-7	1.9	2
723	Role of thalidomide in previously untreated patients with multiple myeloma. 2008 , 8, 1569-80		4
722	Vascular complications of selected cancer therapies. 2008 , 5, 797-805		59
721	The role of novel drugs in multiple myeloma. 2008 , 19 Suppl 7, vii121-7		5
720	Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. 2008 , 12, 21-8		14
719	Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. 2008 , 5, 374-5		1

718	Lenalidomide and its role in the management of multiple myeloma. 2008 , 8, 865-74		14
717	Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. <i>Blood</i> , 2008 , 112, 4924-34	2.2	59
716	TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA. 26-36		
715	Advances in therapy of multiple myeloma. 2008 , 20, 697-704		25
714	Bibliography. Current world literature. Renal and urological problems. 2008 , 2, 223-7		
713	New drugs in multiple myeloma. 2008 , 2, 204-10		8
712	Front line treatment of elderly multiple myeloma in the era of novel agents. 2008 , 99		
711	Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide. 2009 , 1, CMT.S2295		
710	Supportive therapies in multiple myeloma. 2009 , 7, 971-9		3
709	Lenalidomide in multiple myeloma. 2009 , 9, 1559-70		3
708	Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. 2009 , 27, 5713-9		141
707	Drug-induced hematologic syndromes. 2009 , 2009, 495863		61
706	Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. 2009 , 19, 355-64		20
705	Thromboembolische Erkrankungen in der Hämatologie und Onkologie / Thrombotic disease in cancer patients. 2009 , 33, 133-139		
704	Thrombotic disease in cancer patients1. 2009 , 33, ---		
703	How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. 2009 , 566-77		33
702	Emerging therapies for multiple myeloma. 2009 , 14, 99-127		40
701	Coagulation in Hematological Malignancies. 2009 , 27, 7-16		

700	Catheter-associated thrombosis in patients with malignancy. 2009 , 27, 4858-64		60
699	Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. 2009 , 27 Suppl 1, 63-74		120
698	Management of venous thromboembolism and the potential to impact overall survival in patients with cancer. 2009 , 29, 1344-56		4
697	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009 , 82, 93-105	3.8	17
696	Langerhans cell histiocytosis following acute leukemia in an adult. <i>American Journal of Hematology</i> , 2009 , 84, 693-4	7.1	6
695	Treatment of multiple myeloma in patients with Gaucher disease. <i>American Journal of Hematology</i> , 2009 , 84, 694-6	7.1	17
694	Two cases of pegylated asparaginase-associated severe and persistent hyperbilirubinemia. <i>American Journal of Hematology</i> , 2009 , 84, 696	7.1	0
693	Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia. <i>American Journal of Hematology</i> , 2009 , 84, 697-8	7.1	2
692	Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. <i>American Journal of Hematology</i> , 2009 , 84, 698-9	7.1	16
691	Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2009 , 84, 699	7.1	3
690	Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2009 , 84, 699-701	7.1	35
689	Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. <i>American Journal of Hematology</i> , 2009 , 84, 701-2	7.1	29
688	Novel agents in myeloma: an exciting saga. 2009 , 115, 236-42		4
687	Treatment of relapsed and refractory myeloma. 2009 , 4, 99-107		5
686	Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. 2009 , 88, 67-71		45
685	Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2009 , 145, 151-63	4.5	75
684	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2009 , 145, 681-708	4.5	26
683	Treatment of newly diagnosed myeloma. <i>Leukemia</i> , 2009 , 23, 449-56	10.7	74

682	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009 , 23, 1716-30	10.7	123
681	United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. 2009 , 31, 119-31		1
680	Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. 2009 , 22, 1-4		13
679	Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). 2009 , 10, 1-15		6
678	Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. 2009 , 53, 2231-47		885
677	Epidemiology of cancer-related venous thromboembolism. 2009 , 22, 9-23		145
676	Risk stratification for cancer-associated venous thromboembolism. 2009 , 22, 35-47		29
675	Treatment of multiple myeloma in the targeted therapy era. 2009 , 43, 329-38		11
674	Treatment of multiple myeloma: a comprehensive review. 2009 , 9, 278-88		117
673	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. 2009 , 2009, 704928		12
672	Venous thromboembolism in the hematologic malignancies. 2009 , 27, 4848-57		144
671	Coagulation in Cancer. 2009 ,		4
670	Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1442-7	1.9	37
669	New generation pharmacotherapy in elderly multiple myeloma patients. 2009 , 10, 81-98		3
668	Immunomodulatory agents in oncology. 2009 , 3, 170-181		2
667	Managing the side effects of lenalidomide and bortezomib. 2009 , 6, 56-57		
666	Frontline treatment in elderly patients with multiple myeloma. 2009 , 46, 133-42		5
665	Treatment of relapsed/refractory multiple myeloma. 2009 , 46, 143-57		43

664	Front-line treatment in younger patients with multiple myeloma. 2009 , 46, 118-26		13
663	Multiple myeloma. 2009 , 374, 324-39		605
662	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. 2009 , 84, 1095-110		199
661	Cancer-associated thrombosis. 2009 , 16, 378-85		17
660	Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. 2009 , 15, 473-8		3
659	Novel agents for relapsed and/or refractory multiple myeloma. 2009 , 15, 485-93		2
658	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009 , 114, 5436-43	2.2	116
657	Thalidomide in multiple myeloma in the elderly. 2009 , 5, 7-18		
656	Acquired thrombotic risk factors in the critical care setting. 2010 , 38, S43-50		29
655	The role of thromboprophylaxis in cancer patients: emerging data. 2010 , 17, 450-6		8
654	Thromboembolic events in patients treated with anti-angiogenic drugs. 2010 , 8, 102-13		30
653	The Belgian 2010 consensus recommendations for the treatment of multiple myeloma. 2010 , 65, 252-64		
652	The lack of ties between north-eastern Italy and African-Americans suggest a multi-founder effect for FVII Padua (Arg304Gln) disorder. 2010 , 21, 775-6		3
651	New oral anticoagulants might be useful thromboprophylactic agents in multiple myeloma patients on immunomodulatory agents. 2010 , 21, 776-8		
650	Swine flu: any effect on the platelets?. 2010 , 21, 778		
649	High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. <i>Blood</i> , 2010 , 116, 22-6	2.2	62
648	Threatening clots in MGUS and myeloma. <i>Blood</i> , 2010 , 115, 4975-6	2.2	4
647	Arterial thrombosis complicates myeloma?. <i>Blood</i> , 2010 , 116, 2-3	2.2	6

646	Diastolic dysfunction in sickle cell. <i>Blood</i> , 2010 , 116, 1-2	2.2	47
645	Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. <i>Blood</i> , 2010 , 116, 1405-12	2.2	207
644	Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). <i>Blood</i> , 2010 , 116, 5838-41	2.2	154
643	Cardio-oncology/onco-cardiology. 2010 , 33, 733-7		59
642	Treatment of multiple myeloma and arterial thrombosis. 2010 , 89, 419-20		3
641	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. 2010 , 89, 201-6		23
640	Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. 2010 , 89, 803-11		28
639	A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. 2010 , 89, 1019-27		14
638	Les nouveaux médicaments du myélome. 2010 , 12, 353-361		
637	Therapieoptionen im Rezidiv des multiplen Myeloms. 2010 , 16, 282-288		
636	Supportive Therapie bei multiplem Myelom. 2010 , 16, 298-308		
635	Multiple myeloma: management of adverse events. 2010 , 27, 646-53		16
634	Advances in treatment for relapses and refractory multiple myeloma. 2010 , 27 Suppl 1, S25-42		9
633	Management of disease- and treatment-related complications in patients with multiple myeloma. 2010 , 27 Suppl 1, S43-52		18
632	Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. 2010 , 92, 118-26		38
631	Venous thromboembolism and cancer: a systematic review. 2010 , 30, 67-78		33
630	Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. <i>European Journal of Haematology</i> , 2010 , 84, 484-92	3.8	22
629	Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. <i>European Journal of Haematology</i> , 2010 , 85, 181-91	3.8	13

628	Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2010 , 85, 213-5	7.1	2
627	ASH 2009 meeting report—Top 10 clinically oriented abstracts in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
626	ASH 2009 meeting report—Top 10 clinically-oriented abstracts in hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
625	ASH 2009 meeting report—Top 10 clinically oriented abstracts in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
624	ASH 2009 meeting report—Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
623	ASH 2009 meeting report—Top 10 clinically oriented abstracts in sickle cell disease. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
622	ASH 2009 meeting report—Top 10 clinically oriented abstracts in multiple myeloma. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
621	ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2010 , 85, NA-NA	7.1	
620	How best to use new therapies in multiple myeloma. 2010 , 24, 91-100		10
619	Lenalidomide: an update on evidence from clinical trials. 2010 , 24 Suppl 1, S21-6		8
618	Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. <i>Leukemia</i> , 2010 , 24, 1350-6	10.7	68
617	Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2010 , 24, 1037-42	10.7	33
616	Anti-angiogenesis therapies: their potential in cancer management. 2010 , 3, 69-82		32
615	Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. 2010 , 8 Suppl 1, S13-20		14
614	Management of patients with chronic lymphocytic leukemia treated with lenalidomide. 2010 , 14, 491-9		7
613	Angiogenèse, traitement héparinique et pathologies cancéreuses. 2010 , 16, 129-142		0
612	Palliative oncology: thalidomide. 2010 , 27, 198-204		5
611	Multiple myeloma. 2010 , 21 Suppl 7, vii313-9		29

610	Thrombosis in multiple myeloma. 2010 , 2010, 437-44	71
609	Drug-induced thromboembolic events in patients with malignancy. 2010 , 10, 94-102	3
608	State-of-the-Art Management of Complications of Myeloma and Its Treatment. 2010 , 2010, 343089	4
607	Current multiple myeloma treatment strategies with novel agents: a European perspective. 2010 , 15, 6-25	77
606	Relapsed multiple myeloma. 2010 , 2010, 303-9	33
605	Cost-effectiveness of lenalidomide in multiple myeloma. 2010 , 10, 229-38	7
604	Lenalidomide in multiple myeloma: current role and future directions. 2010 , 11, 829-42	10
603	[Update on the use of estramustin in metastatic prostate cancer]. 2010 , 20, 24-9	1
602	The current status and future of multiple myeloma in the clinic. 2010 , 10, 28-43	20
601	Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. 2010 , 10, 138-43	16
600	Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. 2010 , 10, 353-60	4
599	Ten years of improvement in the management of multiple myeloma: 2000-2010. 2010 , 10, 424-42	22
598	Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. 2010 , 7, 564-75	246
597	Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. 2010 , 46, 1790-9	28
596	The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. 2010 , 125, 216-9	17
595	Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. 2010 , 125 Suppl 2, S1-7	61
594	Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. 2010 , 125 Suppl 2, S96-102	34
593	Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. 2010 , 125 Suppl 2, S108-16	30

592	Management of treatment-related adverse events in patients with multiple myeloma. 2010 , 36 Suppl 2, S24-32	53
591	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. 2010 , 11, 29-37	760
590	Treatment of thromboembolism in cancer patients. 2010 , 11, 2049-58	6
589	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1424-43	43
588	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. 2010 , 28, 5101-9	368
587	Managing multiple myeloma in the elderly: are we making progress?. 2011 , 4, 301-15	6
586	The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. 2011 , 29, 269-85	13
585	Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 2011 , 29, 986-93	253
584	Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. 2011 , 11, 228-36	51
583	Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. 2011 , 11, 414-20	8
582	Management of myeloma: an Italian perspective. 2011 , 11 Suppl 1, S82-6	
581	Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. 2011 , 11, 38-43	54
580	Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma. 2011 , 113, 488-9	4
579	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. 2011 , 37, 266-83	62
578	Myelome multiple : diagnostic clinique et perspective de traitement. Recommandations de l'International Myeloma Working Group (IMWG). 2011 , 26, 125-136	6
577	Immunomodulatory drugs increase endothelial tissue factor expression in vitro. 2011 , 127, 264-71	17
576	[Update in thrombosis and cancer]. 2011 , 32, 265-7	0
575	Multiple myeloma. 2011 , 364, 1046-60	1724

574	Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. 2011 , 48, 46-54		10
573	Safety and efficacy of zoledronic acid in multiple myeloma. 2011 , 377, 2178		3
572	Thrombosis and malignant hemopathies: truths and realities. 2011 , 17, 183-188		
571	Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. 2011 , 105, 14-20		90
570	Management of cardiac and pulmonary treatment-related side effects. 2011 , 67-94		2
569	[Venous thrombembolism in tumour patients]. 2011 , 31, 281-90; quiz 291-2		7
568	Activation of coagulation by a thalidomide-based regimen. 2011 , 22, 532-40		13
567	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. 2011 , 8, 415-429		3
566	Myeloma multiple. 2011 , 6, 1-12		1
565	Lenalidomide: from relapsed/refractory multiple myeloma to upfront therapy. 2011 , 7, 665-676		
564	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011 , 117, 6063-73	2.2	234
563	Evolving paradigms in the treatment of newly diagnosed multiple myeloma. 2011 , 9, 1186-96		8
562	Risk assessment and prophylaxis for VTE in cancer patients. 2011 , 9, 789-97		33
561	Venous thromboembolic disease. 2011 , 9, 714-77		57
560	The use of estramustine phosphate in the modern management of advanced prostate cancer. 2011 , 108, 1782-6		30
559	Guidelines for the diagnosis and management of multiple myeloma 2011. <i>British Journal of Haematology</i> , 2011 , 154, 32-75	4.5	224
558	Guidelines for supportive care in multiple myeloma 2011. <i>British Journal of Haematology</i> , 2011 , 154, 76-103		138
557	Poor tolerability of thalidomide in end-stage oesophageal cancer. 2011 , 20, 593-600		21

556	Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 312-9	15.4	147
555	Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 653-63	15.4	119
554	The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. <i>Leukemia</i> , 2011 , 25, 538-50	10.7	95
553	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011 , 25, 689-96	10.7	94
552	A review of the history, properties, and use of the immunomodulatory compound lenalidomide. 2011 , 1222, 76-82		52
551	Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. <i>European Journal of Haematology</i> , 2011 , 86, 16-22	3.8	121
550	Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. <i>European Journal of Haematology</i> , 2011 , 86, 129-34	3.8	21
549	Thalidomide. 2011 , 41, 140-5		4
548	Anticoagulation in the management of venous thromboembolism in the cancer patient. 2011 , 31, 282-94		14
547	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, SB Paulo, Brazil. 2011 , 32, 242-66		2
546	Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. 2011 , 28 Suppl 1, 11-6		15
545	Management of the adverse effects of lenalidomide in multiple myeloma. 2011 , 28 Suppl 1, 1-10		8
544	Light chain (AL) amyloidosis: update on diagnosis and management. 2011 , 4, 47		53
543	Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2011 , 86, 57-65	7.1	109
542	ASH 2010 meeting report Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders. <i>American Journal of Hematology</i> , 2011 , 86, 443-445	7.1	
541	Inflammation, TNF α and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2011 , 86, 835-40	7.1	24
540	Management of older patients with multiple myeloma. 2011 , 25, 65-73		24
539	Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?. 2011 , 25, 181-91		43

538	A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1942-8	1.9	27
537	Management of hematological malignancies in patients affected by renal failure. 2011 , 11, 415-32		7
536	Multiple Myeloma. 2011 ,		2
535	Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. 2011 , 29, 316-23		51
534	Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. 2011 , 16, 388-403		23
533	Treatment options for relapsed and refractory multiple myeloma. 2011 , 17, 1264-77		103
532	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. <i>Leukemia</i> , 2011 , 25, 749-60	10.7	97
531	Treatment of multiple myeloma. 2011 , 8, 479-91		205
530	Venous thromboembolism in the hematologic malignancies. 2012 , 24, 702-10		41
529	European perspective on multiple myeloma treatment strategies: update following recent congresses. 2012 , 17, 592-606		43
528	Multiple myeloma: improved outcomes with new therapeutic approaches. 2012 , 6, 330-6		16
527	Thalidomide-associated thrombosis in the treatment of HIV-associated severe aphthous disease: a case report and review of the literature. 2012 , 11, 345-7		1
526	Clinical experience with thalidomide and lenalidomide in multiple myeloma. 2012 , 12, 372-90		7
525	Thrombotic and bleeding complications associated with chemotherapy. 2012 , 38, 808-17		6
524	Thromboprophylaxis in multiple myeloma: is the evidence there?. 2012 , 12, 291-4		1
523	Evaluating surface erythropoietin receptor in multiple myeloma. <i>Leukemia</i> , 2012 , 26, 1883-6	10.7	2
522	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with International Staging System stage II or III, or extramedullary disease. <i>Leukemia and Lymphoma</i> , 2012 , 53, 275-81	1.9	12
521	A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. 2012 , 8, e158-67		4

520	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. 2012 , 8, 1209-22		8
519	Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. 2012 , 6, 1-10		7
518	Thrombosis in hematologic malignancies: risks and consequences. 2012 , 1, 87-95		
517	Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma. 2012 , 2012, 607260		5
516	Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. 2012 , 3, 115-22		4
515	Thrombosis in multiple myeloma (MM). 2012 , 17 Suppl 1, S177-80		30
514	Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium. 2012 , 12, 743-56		10
513	Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. 2012 , 24 Suppl 2, S13-20		1
512	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. <i>Haematologica</i> , 2012 , 97, 784-91	6.6	43
511	Myeloma: diagnosis complications and supportive care. 2012 , 17 Suppl 1, S109-11		1
510	Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. <i>Haematologica</i> , 2012 , 97, 442-50	6.6	121
509	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012 , 119, 933-9; quiz 1093	2.2	212
508	When a little aspirin may be enough. <i>Blood</i> , 2012 , 119, 905-6	2.2	4
507	Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. 2012 , 49 Suppl 1, S16-32		27
506	[Newly diagnosed multiple myeloma: Do we need to propose thromboprophylaxis?]. 2012 , 33, 693-6		
505	Targeting Galectin-3 Unveils the Complexity of Multiple Myeloma: A Sweet Context. 2012 , 289-307		
504	Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. 2012 , 108, 1042-8		53
503	Mieloma múltiple. 2012 , 45, 1-13		

502	Risk assessment for cancer-associated thrombosis: what is the best approach?. 2012 , 129 Suppl 1, S10-5	30
501	Risk and management of thrombosis in multiple myeloma. 2012 , 129 Suppl 1, S88-92	17
500	Synthesis et conclusion. 2012 , 14, 667-670	
499	Zalecenia Polskiej Grupy Szpiczakowej dotyczce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. 2012 , 43, 7-47	3
498	Thrombosis in myeloma treated with IMiDs. 2012 , 130 Suppl 1, S63-5	6
497	[Management of thromboembolic risk in patients with cancer]. 2012 , 139 Suppl 2, 31-5	2
496	How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. 2012 , 36 Suppl 1, S35-43	14
495	The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. 2012 , 11, 107-20	14
494	Emerging biological insights and novel treatment strategies in multiple myeloma. 2012 , 17, 407-38	12
493	Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. 2012 , 5, 617-26; quiz 627	14
492	Hematologic malignancies and thrombosis. 2012 , 129, 360-6	33
491	Ask the Experts: Deriving new treatment strategies in multiple myeloma. 2012 , 1, 21-26	
490	Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma. 2012 , 6, 125	5
489	Thrombosis and cancer. 2012 , 9, 437-49	84
488	Latest advances and current challenges in the treatment of multiple myeloma. 2012 , 9, 135-43	165
487	Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 2599-601	15.4 27
486	Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. 2012 , 12, 191-6	19
485	Thrombotic risk in patients undergoing peripheral stem cell apheresis and low-molecular weight heparin prophylaxis pre-apheresis. 2012 , 47, 229-34	2

484	The application and biology of immunomodulatory drugs (IMiDs) in cancer. 2012 , 136, 56-68		49
483	Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. 2012 , 91, 1773-8		16
482	Liquid tumors in the elderly. 2012 , 28, 115-52		
481	Myeloma and Leukemia. 2012 , 509-529		
480	Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. <i>Leukemia</i> , 2012 , 26, 73-85	10.7	71
479	Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. 2012 , 8, 1223-38		10
478	Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. 2012 , 3, 255-66		29
477	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. 2012 , 4, 253-68		26
476	Lenalidomide and Dexamethasone Regimen for Multiple Myeloma. 2012 , 47, 343-347		
475	Multiple Myeloma: Supportive Care Requirements and Coordination of Patient-Centered Care. 2012 , 18, S20-S25		
474	Cancer-associated thrombosis: updates and controversies. 2012 , 2012, 626-630		49
473	Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?. 2012 , 2012, 354-361		23
472	Lenalidomide in multiple myeloma: Current status and future potential. <i>American Journal of Hematology</i> , 2012 , 87, 1089-95	7.1	19
471	Risk assessment models for cancer-associated venous thromboembolism. 2012 , 118, 3468-76		26
470	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. 2012 , 34, 143-63		
469	Chemotherapy-induced cardiotoxicity. 2012 , 9, 117-27		45
468	Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 156, 552-5; author reply 555	4.5	30
467	Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 962-4	15.4	3

466	Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. 2012 , 8, 319-24		1
465	Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. <i>European Journal of Haematology</i> , 2012 , 88, 485-96	3.8	38
464	Pre-existing diabetes mellitus in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012 , 89, 320-7	3.8	17
463	Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. 2012 , 118, 549-57		37
462	Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 78-88	7.1	106
461	Cancer and coagulation. <i>American Journal of Hematology</i> , 2012 , 87 Suppl 1, S82-7	7.1	56
460	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. 2012 , 91, 249-56		13
459	Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. 2013 , 7, 52		8
458	Side Effects of Medical Cancer Therapy. 2013 ,		2
457	How lenalidomide is changing the treatment of patients with multiple myeloma. 2013 , 88 Suppl 1, S23-35		20
456	Therapeutic effects of thalidomide in hematologic disorders: a review. 2013 , 7, 290-300		9
455	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. 2013 , 13, 1731-40		28
454	Management of multiple myeloma in Asia: resource-stratified guidelines. 2013 , 14, e571-81		31
453	A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. 2013 , 131, 140-4		6
452	Incorporating novel agents in the management of elderly myeloma patients. 2013 , 8, 261-9		4
451	Catheter-related thrombosis in cancer patients. <i>British Journal of Haematology</i> , 2013 , 162, 748-57	4.5	26
450	Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. 2013 , 9, 169-75		8
449	Diagnosis and Treatment of Multiple Myeloma. 2013 , 637-663		2

448	Kardionkologia [odpowiedŃa wyzwania wspŃczesnej terapii. 2013 , 10, 11-23		
447	Zalecenia Polskiej Grupy Szpiczakowej dotyczŃce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013. 2013 , 44, 3-47		4
446	Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. 2013 , 31, 2189-204		640
445	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013 , 160, 351-8	4.5	16
444	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 56-70	15.4	383
443	International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 71-80	15.4	177
442	Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2013 , 88, 226-35	7.1	92
441	Immunomodulatory drugs in multiple myeloma. 2013 , 6, 69-82		37
440	Coagulation and cancer: biological and clinical aspects. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 223-33	15.4	257
439	Second auto-SCT for treatment of relapsed multiple myeloma. 2013 , 48, 568-73		47
438	Bleeding and Thrombosis in Hematologic Neoplasia. 2013 , 1363-1385		1
437	Management of older adults with multiple myeloma. 2013 , 27, 133-42		50
436	Perspectives in the treatment of multiple myeloma. 2013 , 13 Suppl 1, S1-22		17
435	Cardioncology: state of the heart. 2013 , 168, 680-7		54
434	Novel immunomodulatory compounds in multiple myeloma. 2013 , 22, 207-15		8
433	Thrombosis and Cancer. 2013 , 408-422		
432	Primary venous thromboembolism prophylaxis in ambulatory cancer patients. 2013 , 47, 198-209		7
431	Understanding, recognizing, and managing toxicities of targeted anticancer therapies. 2013 , 63, 249-79		222

430	[Management of catheter-related upper extremity deep vein thrombosis]. 2013 , 138 Suppl 2, e86-94		2
429	Treatment for high-risk smoldering myeloma. 2013 , 369, 1764-5		53
428	Quality of life and supportive care in multiple myeloma. 2013 , 30, 234-46		24
427	Cancer and venous thrombosis: current comprehensions and future perspectives. 2013 , 39, 507-14		13
426	Cardiotoxicity. 2013 , 483-530		1
425	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013 , 88, 765-70	7.1	26
424	Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. 2013 , 2, S21-7		7
423	Cancer-associated thrombosis. 2013 , 2013, 684-91		56
422	Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. <i>Blood</i> , 2013 , 122, 2799-806	2.2	70
421	Non-Hodgkin's lymphomas, version 1.2013. 2013 , 11, 257-72; quiz 273		43
420	Traitement du myélome multiple. 2013 , 8, 1-16		
419	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. <i>Haematologica</i> , 2013 , 98, 776-83	6.6	31
418	Venous thromboembolic disease. 2013 , 11, 1402-29		73
417	MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. 2013 , 110, 844-51		44
416	Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. 2013 , 8, e64369		7
415	Multiple myeloma: an update. 2013 , 28, 3-11		24
414	Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective. 2013 , 155		
413	Plasma Cell Neoplasms: MGUS and Myeloma. 2014 , 1713-1719		

412	. 2014,	2
411	Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. 2014 , 14, 499-510	16
410	Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. 2014 , 46, 240-53	37
409	A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. 2014 , 35, 130-8	2
408	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. 2014 , 64, 422-44	61
407	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. <i>Leukemia</i> , 2014 , 28, 1573-85	10.7 84
406	Lenalidomide versus bortezomib: an indirect comparison. 2014 , 3, 131-136	2
405	Risk assessment for thrombosis in cancer. 2014 , 40, 319-24	35
404	Venous Thromboembolism in Cancer Patients. 2014 , 42, 24-33	7
403	An evaluation of current treatment options for immunoglobulin light-chain amyloidosis. 2014 , 2, 229-244	
402	Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know?. 2014 , 203, 1353-62	13
401	Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1816-21	15.4 13
400	The coagulopathy of cancer. 2014 , 21, 423-9	57
399	Management of venous thromboembolism in cancer patients. 2014 , 2, 24-36	2
398	Venous thromboembolism in multiple myeloma. 2014 , 40, 338-47	41
397	Current strategies for treatment of relapsed/refractory multiple myeloma. 2014 , 7, 97-111	58
396	Management of complications related to central venous catheters in cancer patients: an update. 2014 , 40, 382-94	15
395	The Coagulation Consult. 2014 ,	1

394	Small Molecules in Oncology. 2014,		3
393	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-92	10.7	132
392	Phlebology, Vein Surgery and Ultrasonography. 2014,		1
391	General Surgery Risk Reduction. 2014,		
390	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. 2014, 32, 587-600		255
389	Multiple Myeloma. 2014,		9
388	Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. 2014, 4, e257		31
387	Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 999-1009	7.1	123
386	Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. 2014, 38, 1048-54		13
385	Relapsed and refractory multiple myeloma: new therapeutic strategies. 2014, 28, 861-90		2
384	Therapy for cancer-related thromboembolism. 2014, 41, 319-38		19
383	Risk stratification strategies for cancer-associated thrombosis: an update. 2014, 133 Suppl 2, S35-8		76
382	Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. 2014, 134, 404-11		7
381	Advances in supportive care for multiple myeloma. 2014, 12, 502-11		17
380	Cancer and Thrombosis. 2014, 284-295		
379	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-32	2.2	271
378	Multiple myeloma treatment and management in the elderly. 2014, 29, 434-8, 440-4, 446-51		7
377	Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. 2015, 41, 756-64		59

376	A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. 2015 , 5, 11	10
375	Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers. 2015 , 29, 1119-20	0
374	Thromboembolic risk in hematological malignancies. 2015 , 53, 1139-47	4
373	Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. 2015 , 26, 621-7	13
372	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. 2015 , 128, 1215-22	13
371	Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. 2015 , 8, 1277-84	
370	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. 2015 , 50, 7-18	3
369	A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. 2015 , 10, e0121197	8
368	Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. 2015 , 11, 1643-58	
367	The mechanisms of cancer-associated thrombosis. 2015 , 135 Suppl 1, S8-S11	81
366	Managing multiple myeloma in the over 70s: a review. 2015 , 80, 148-54	6
365	Treatment-related symptom management in patients with multiple myeloma: a review. 2015 , 23, 1431-45	27
364	Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. 2015 , 39, 245-9	18
363	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. 2015 , 21, 1155-66	87
362	Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting. 2015 , 35, 455-61	6
361	An update on the use of lenalidomide for the treatment of multiple myeloma. 2015 , 16, 1865-77	8
360	Approach to chemotherapy-associated thrombosis. 2015 , 20, 153-61	38
359	Prevention of thromboembolism in myeloma: expanding the tool-box of assays to predict the risk?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3246-7	1.9

358	Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide. 2015 , 102, 271-7		2
357	Venous thromboembolism in cancer patients: an underestimated major health problem. 2015 , 13, 204		70
356	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. 2015 , 15, 592-8		2
355	Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. 2015 , 133, 372-380		2
354	Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. <i>British Journal of Haematology</i> , 2015 , 168, 511-7	4.5	9
353	European Myeloma Network guidelines for the management of multiple myeloma-related complications. <i>Haematologica</i> , 2015 , 100, 1254-66	6.6	222
352	Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder. 2015 , 465, 678-84		6
351	Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. 2015 , 136, 974-9		7
350	Multiple myeloma. 2015 , 385, 2197-208		401
349	Management of Hematological Cancer in Older People. 2015 ,		
348	Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. 2015 , 94, 643-9		11
347	Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma. 2016 , 102,		8
346	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. 2016 , 6, 21-35		0
345	Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?. 2016 , 9, 4843-58		4
344	The Diagnosis and Treatment of Multiple Myeloma. 2016 , 113, 470-6		73
343	Clinical practice guidelines for prophylaxis of venous thromboembolism in cancer patients. 2016 , 116, 618-25		16
342	Multiple myeloma in the very elderly patient: challenges and solutions. 2016 , 11, 423-35		23
341	Multiple Myeloma Presenting with NSTEMI. 2016 , 01, 029-031		

340	Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. <i>American Journal of Hematology</i> , 2016 , 91, E455-6	7.1	2
339	Oncology. 2016 , 355-378		
338	A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. 2016 , 6, e422		5
337	Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?. 2016 , 143, 101-2		5
336	Prophylaxis of venous thromboembolism in cancer patients. 2016 , 9, 535-9		6
335	Venous thromboembolism in cancer patients: risk assessment, prevention and management. 2016 , 12, 221-35		2
334	Cancer-associated thrombosis. 2016 , 62, 121-58		37
333	Nuances in the Management of Older People With Multiple Myeloma. 2016 , 11, 241-51		11
332	Update of thrombosis in multiple myeloma. 2016 , 140 Suppl 1, S76-80		31
331	Cancer associated thrombosis: risk factors and outcomes. 2016 , 140 Suppl 1, S12-7		38
330	Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. 2016 , 141, 84-90		26
329	Prevention of Venous Thromboembolism. 2016 , 429-443		
328	Deferasirox in thalassemia patients with end-stage renal disease. <i>American Journal of Hematology</i> , 2016 , 91, E456-7	7.1	3
327	Rare Coagulation Factor Deficiencies: Diagnosis and Management. 2016 , 273-283		
326	Venous thrombotic events in patients admitted to a tuberculosis centre. 2017 , 110, 215-218		5
325	Hematopoietic Cell Transplantation for Multiple Myeloma. 2016 , 625-639		
324	Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. 2016 , 145, 119-25		6
323	Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2016 , 91, 719-34	7.1	279

322	Update on cardiotoxicity of anti-cancer treatments. 2016 , 46, 264-84		46
321	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, 101-8	7.1	16
320	Myeloma today: Disease definitions and treatment advances. <i>American Journal of Hematology</i> , 2016 , 91, 90-100	7.1	105
319	Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus. 2016 , 28, 9573-9580		147
318	High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy. 2016 , 96, 399-405		17
317	Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. 2016 , 134, e32-69		210
316	Thromboprophylaxis in Cancer Patients. 2016 , 97-109		
315	Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy. 2016 , 22, 248-55		8
314	New Therapeutic Agents in Thrombosis and Thrombolysis. 2016 ,		6
313	Myeloma. 2016 , 89-100		
312	Prophylaxie primaire de la maladie thromboembolique veineuse chez les patients cancéreux ambulatoires traités par les antiñoplasiques. 2016 , 18, 23-31		
311	Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. 2016 , 32, 863-870.e5		43
310	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. 2016 , 77, 575-81		5
309	[Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?]. 2016 , 37, 473-9		3
308	Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data. 2016 , 60, 294-308		40
307	Cardiovascular Complications of Novel Multiple Myeloma Treatments. 2016 , 133, 908-12		26
306	Effets cardiovasculaires graves des chimiothérapies, thérapies ciblées et des traitements immunosuppresseurs. 2016 , 25, 123-136		4
305	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016 , 30, 1005-17	10.7	159

304	Venous thromboembolism in hematopoietic stem cell transplant recipients. 2016 , 51, 473-8		14
303	Safety and efficacy of primary thromboprophylaxis in cancer patients. 2017 , 19, 1-11		14
302	Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. 2017 , 8, 1-7		17
301	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. 2017 , 77, 505-520		84
300	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. 2017 , 112, 153-170		27
299	How I manage the toxicities of myeloma drugs. <i>Blood</i> , 2017 , 129, 2359-2367	2.2	28
298	Treating Multiple Myeloma Patients With Oral Therapies. 2017 , 17, 243-251		21
297	Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. 2017 , 26, 578-586		12
296	Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. 2017 , 12, 257-267		2
295	Pulmonary Toxicities from Conventional Chemotherapy. 2017 , 38, 209-222		16
294	Cardio-Oncology. 2017 ,		1
293	Coagulopathic Complications of Cancer Patients. 2017 , 1-11		
292	Vascular Complications of Cancer and Cancer Therapy. 2017 , 215-240		
291	New Agents in Multiple Myeloma: An Examination of Safety Profiles. 2017 , 17, 391-407.e5		32
290	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 571-582	4.5	39
289	Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. 2017 , 17, 75-87		1
288	Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre. 2017 , 52, 962-968		5
287	Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma. 2017 , 17, 585-591		9

286	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. 2017 , 18, 1061-1079		3
285	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. 2017 , 65, 1-7		19
284	Circulating tumor cells and coagulation-Minireview. 2017 , 114, 33-42		12
283	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. 2017 , 92, 578-598		88
282	Myeloma in the Real World: What Is Really Happening?. 2017 , 17, 133-144.e1		22
281	Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 941-949	1.9	14
280	Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2 -line therapy for relapsed and refractory multiple myeloma - a phase II trial. <i>British Journal of Haematology</i> , 2017 , 176, 770-782	4.5	13
279	Thromboembolic Disorders as a Consequence of Cancer. 2017 , 57-74		
278	Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma. 2017 , 52, 27-32		3
277	New Treatment Methods in Multiple Myeloma. 2017 , 2, 144-149		0
276	Mechanisms and risk factors of thrombosis in cancer. 2017 , 118, 79-83		118
275	Use of direct oral anticoagulants in patients on immunomodulatory agents. 2017 , 44, 298-302		12
274	Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma. 2017 , 33, 332-347		2
273	Immunotherapy in Multiple Myeloma. 2017 , 33, 292-298		1
272	Cardiovascular complications of multiple myeloma in the elderly. 2017 , 15, 933-943		10
271	Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. 2017 , 70, 2552-2565		144
270	Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. 2017 , 33, 254-264		1
269	Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma. 2017 , 33, 279-291		4

268	Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment?. 2017 , 21, 240-249		15
267	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. <i>Leukemia</i> , 2017 ,	10.7	7
266	Strategie optymalizacji terapii lenalidomidem u chorych na szpiczaka plazmocytoowego. 2017 , 48, 282-290		
265	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. 2017 , 9, e1258		5
264	Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention. 2018 , 20, 19		13
263	Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature. 2018 , 124, 41-50		20
262	Small bowel bleeding: cause and the role of endoscopy and medical therapy. 2018 , 34, 165-174		6
261	Anticoagulation in the Patient with Cancer. 2018 , 425-440		1
260	Thrombophilic States. 2018 , 325-343		
259	Serum Free Light Chain Difference and κ Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis. 2018 , 18, 408-414		4
258	Other Complications of Multiple Myeloma. 2018 , 141-156		1
257	Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016. 2018 , 36, 73-91		
256	Multiple Myeloma. 2018 , 463-483		
255	Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. <i>European Journal of Haematology</i> , 2018 , 100, 518-525	3.8	10
254	Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. 2018 , 13, 114-124		16
253	Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. 2018 , 107, 541-550		10
252	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018 , 32, 1542-1560	10.7	40
251	Nanotherapeutics for multiple myeloma. 2018 , 10, e1526		7

250 Supportive Care in Multiple Myeloma. **2018**, 595-607

249 Bleeding and Thrombosis in Hematologic Neoplasia. **2018**, 1263-1289

1

248 Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. **2018**, 551-571

247 Primer on Chronic Lymphocytic Leukemia: Part II. **2018**, 14, 309-315.e2

246 Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. *British Journal of Haematology*, **2018**, 180, 271-275 4.5 16

245 Personalized Therapy for Multiple Myeloma. **2018**,

1

244 Overview of small bowel angioectasias: clinical presentation and treatment options. **2018**, 12, 125-139

12

243 Managing multiple myeloma in elderly patients. *Leukemia and Lymphoma*, **2018**, 59, 1300-1311

1.9 11

242 Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score. **2017**, 35, 5

23

241 Treatment of Patients in First or Second Relapse. **2018**, 77-102

240 Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. **2018**, 55, 182-184

1

239 Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma. **2018**, 52, 1981-1990

4

238 Reply to M.F. Chong et al. **2018**, 36, 828-829

0

237 Collaborative Physician-Pharmacist-Managed Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays. **2018**, 14, e674-e682

13

236 Increased Risk of Ischemic Stroke in Multiple Myeloma Associated With Lenalidomide Treatment: A Case Report and Review of the Literature. **2018**, 41, 232-235

5

235 Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. *British Journal of Haematology*, **2018**, 183, 538-556

4.5 27

234 Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. **2018**, 8, 102

17

233 Unmet Needs and Therapeutic Strategies in Cardio-Hemato-Oncology. **2018**, 140, 226-230

1

232	The Impact of Small Bowel Endoscopy in Patients with Hereditary Hemorrhagic Telangiectasia. 2018 , 35, 300-301		2
231	Special problems in the management of elderly patients with multiple myeloma. 2018 , 58, 64-69		
230	Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. 2018 , 10,		168
229	Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. 2018 , 11, 957-973		6
228	Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms. 2018 , 9, 1058		25
227	The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery. 2018 , 10, 3039-3053		10
226	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018 , 103, 1518-1526	6.6	12
225	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018 , 132, 1114-1124	2.2	28
224	Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018 , 103, 1422-1432	6.6	44
223	Evaluation of Hemostasis. 2018 , 477-497		
222	Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. <i>British Journal of Haematology</i> , 2018 , 182, 513-520	4.5	14
221	Cardiotoxicity. 2018 , 367-406		4
220	Thalidomide remodels developing heart in chick embryo: discovery of a thalidomide mediated hematoma in heart muscle. 2018 , 391, 1093-1105		8
219	Update on the role of lenalidomide in patients with multiple myeloma. 2018 , 9, 175-190		25
218	Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma. 2018 , 9, 1-7		6
217	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. 2018 , 130, 27-35		17
216	Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2018 , 93, 981-1114	7.1	115
215	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019 , 94, 1176-1184	7.1	53

214	Thrombotic Risk from Chemotherapy and Other Cancer Therapies. 2019 , 179, 87-101		22
213	Palliative Care in Patients With Multiple Myeloma. 2019 , 58, 1113-1118		4
212	Thrombosis and Hemostasis in Cancer. 2019 ,		1
211	Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment. 2019 , 36, 72		3
210	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. 2019 , 25, 2261-2266		2
209	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. 2019 , 19, 889-898		3
208	Multiple myeloma: an overview of management. 2019 , 13, 1178224219868235		17
207	Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. 2019 , 48, 141-148		2
206	Immunomodulatory drugs in the treatment of multiple myeloma. 2019 , 49, 695-702		11
205	What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. 2019 , 48, 315-322		5
204	Use of Viscoelastography in Malignancy-Associated Coagulopathy and Thrombosis: A Review. 2019 , 45, 354-372		16
203	Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. <i>American Journal of Hematology</i> , 2019 , 94, 635-640	7.1	25
202	The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2572-2575	1.9	1
201	Updates on thrombotic events associated with multiple myeloma. 2019 , 12, 355-365		6
200	[Primary prophylaxis of venous thromboembolism in ambulatory cancer patients treated with antineoplastic agents]. 2019 , 40, 523-532		
199	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). 2019 , 109, 509-538		11
198	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. 2019 , 286, 63-74		26
197	Management of cardiovascular risk in patients with multiple myeloma. 2019 , 9, 26		37

196	The pharmacologic management of multiple myeloma in older adults. 2019 , 20, 887-902		6
195	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. 2019 , 139, e579-e602		86
194	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. 2019 , 2019,		5
193	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. 2019 , 145, 559-568		7
192	Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. 2019 , 8, 455-462		6
191	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. 2019 , 109, 79-90		7
190	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. 2019 , 14, 21-38		8
189	Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. 2019 , 25, 806-812		5
188	Risk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the National Inpatient Sample, 2011-2015. <i>Leukemia and Lymphoma</i> , 2020 , 61, 370-376	1.9	3
187	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. 2020 , 126, 1640-1650		8
186	Multiple Myeloma and Related Disorders. 2020 , 1884-1910.e7		2
185	Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia. 2020 , 120, 322-328		6
184	Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis. 2020 , 523-543.e7		1
183	Multiple myeloma current treatment algorithms. 2020 , 10, 94		59
182	Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. 2020 , 112, 650-657		1
181	Thrombosis in hematological malignancies: mechanisms and implications. 2020 , 191 Suppl 1, S58-S62		5
180	Assessing the risk of venous thromboembolism in multiple myeloma. 2020 , 191 Suppl 1, S74-S78		2
179	Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. <i>European Journal of Haematology</i> , 2020 , 105, 597-607	3.8	45

178	Thrombosis in the modern era of multiple myeloma. <i>Blood</i> , 2020 , 136, 1019-1021	2.2	1
177	Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. 2020 , 4, pkaa076		7
176	A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
175	Venous thromboembolism in multiple myeloma is associated with increased mortality. 2020 , 4, 1203-1210		3
174	High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. 2020 , 4, 2139-2142		6
173	Thromboprophylaxis in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020 , 190, 493-494		4
172	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020 , 190, 346-357	4.5	8
171	Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committee. 2020 , 42, 200-205		7
170	Cardiac calcified amorphous tumour associated with multiple myeloma. 2020 , 13,		1
169	Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2020 , 95, 548-567	7.1	235
168	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. 2020 , 99, 1793-1804		3
167	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. 2020 , 20, e629-e644		1
166	Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma. 2020 , 27, 1073274820930204		
165	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020 , 95, 672-690	7.1	11
164	Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). 2020 , 45, 28-40		3
163	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. 2020 , 12,		18
162	Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. 2020 , 111, 692-701		6
161	Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1277-1291	1.9	2

160	Risk assessment of venous thromboembolism in hematological cancer patients: a review. 2020 , 13, 471-480		0
159	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. 2020 , 99, 1709-1725		4
158	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020 , 190, 555-561	4.5	14
157	Incidence and risk factors of symptomatic thrombosis related to peripherally inserted central catheter in patients with lung cancer. 2021 , 77, 1284-1292		3
156	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. <i>Blood</i> , 2021 , 137, 896-907	2.2	8
155	Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?. 2021 , 52, 584-589		3
154	Multiple Myeloma. 2021 , 283-301		
153	Bleeding and Thrombosis. 2021 , 491-499		
152	Multiple myeloma. 2021 , 397, 410-427		77
151	Advances in the Management of Cancer-Associated Thrombosis. 2021 , 47, 139-149		5
150	Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. 2021 , 63, 1-6		2
149	Biomimetic Nanoparticles for the Treatment of Hematologic Malignancies. 2021 , 1, 2000047		2
148	Cerebrovascular manifestations in hematological diseases: an update. 2021 , 268, 3480-3492		3
147	Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system. 2021 , 1078155221995885		0
146	CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. <i>European Journal of Haematology</i> , 2021 , 106, 634-642	3.8	9
145	Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. 2021 , 52, 848-853		0
144	Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. 2021 , 18, 401-417		15
143	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021 , 193, 245-268	4.5	3

142	Optimising cardiovascular care of patients with multiple myeloma. 2021 , 107, 1774-1782		0
141	Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a analysis of phase 3 clinical trials. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2219-2226	1.9	1
140	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. <i>British Journal of Haematology</i> , 2021 , 193, 1213-1219	4.5	3
139	Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1852-1863	15.4	3
138	Cancer-Associated Thrombosis: A New Light on an Old Story. 2021 , 9,		5
137	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. 2021 , 11, 121		0
136	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. 2021 , 21, 701-710		1
135	Pretransplant Risk Factors Can Predict Development of Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell Transplantation. 2021 , 18, 1004-1012		1
134	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖHO). 2021 , 13,		2
133	Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. 2021 , 20, 1137-1145		1
132	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021 , 137, 3027-3036	2.2	15
131	Pulmonary Vein Thrombosis in a Patient With Multiple Myeloma on Treatment With Lenalidomide. 2021 , 12, 73-76		0
130	Management of patients with difficult-to-treat multiple myeloma. 2021 , 17, 2089-2105		0
129	Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. 2021 , 1		2
128	Initial Therapeutic Approaches to Patients with Multiple Myeloma. 2021 , 38, 3694-3711		4
127	Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma. 2021 , 21, 812-822		0
126	Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up. <i>JCO Global Oncology</i> , 2021 , 7, 1199-1205	3.7	0
125	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. 2021 , 149, 1980-1996		5

124	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
123	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. 2021 ,		0
122	Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. 2021 , 13,		1
121	Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. 2021 , 9, CD014739		1
120	Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients. 2021 , 1, 259-270		0
119	Oncology. 235-246		1
118	Chemotherapy-associated thrombosis. 2009 , 148, 181-206		8
117	Risk factors for thrombosis in cancer patients. 2009 , 148, 95-114		4
116	General Perioperative Complications. 2014 , 23-105		1
115	Multiple Myeloma. 2018 , 277-284		4
114	Therapy of relapsed and refractory multiple myeloma. 2011 , 183, 239-71		15
113	Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. 2011 , 183, 189-206		18
112	Lenalidomide. 2014 , 201, 347-57		5
111	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. 2017 , 58, 55-71		4
110	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. <i>Blood</i> , 2020 , 136, 1091-1104	2.2	23
109	Upfront Therapy for Myeloma: Tailoring Therapy across the Disease Spectrum. 2012 , 508-14		1
108	[Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy]. 2015 , 87, 4-10		6
107	How I treat elderly patients with plasma cell dyscrasias. 2018 , 10, 4248-4268		5

106	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. 2016 , 7, 59029-59048	14
105	Risk factors for venous and arterial thrombosis. 2011 , 9, 120-38	210
104	Two perspectives on venous thromboembolism in oncology. 2017 , 63, 431-440	1
103	The Current Status and Future of Multiple Myeloma in the Clinic. 2010 , 10, E1-E16	8
102	Novel agents and new therapeutic approaches for treatment of multiple myeloma. 2014 , 4, 73-90	26
101	Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. 2015 , 13, 1398-435	51
100	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. 2019 , 17, 840-847	46
99	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. 2020 , 18, 1685-1717	43
98	Supportive care in multiple myeloma: Current practices and advances. 2021 , 29, 100476	
97	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. 2021 , 13,	1
96	Immune checkpoint inhibitors for cancer and venous thromboembolic events. 2021 , 158, 99-110	7
95	Lenalidomide in Relapsed or Refractory Multiple Myeloma. 2008 , 265-277	
94	Anticoagulants in Cancer. 2009 , 221-236	
93	Treatment of Multiple Myeloma: A Comprehensive Review. 2009 , 3, 65-75	
92	Plasma Cell Tumors: Multiple Myeloma And Solitary Plasmacytoma. 2010 , 1394-1399	
91	Venous Thromboembolism in Patients with Hematologic Malignancies. 2011 , 449-459	
90	Cancer et Vaisseaux. 2011 , 493-503	
89	Pulmonary embolism developing during thalidomide therapy for multiple myeloma in a hemodialysis patient. 2011 , 44, 951-956	

88 Adults Receiving Chemotherapeutic Regimens. 158-183

87 Multiple Myeloma. **2013**, 459-464

86 Newer IMiDs. **2013**, 181-213

85 Multiple Myeloma Surveillance Counterpoint: Australia. **2013**, 493-500

84 Management of Treatment Complications and Supportive Care. **2014**, 159-177

83 Multipel myeloom. **2014**, 135-145

82 Thrombophilias. **2014**, 309-324

81 The Excessively Clotting Cancer Patient. **2014**, 161-183

80 Diagnosis, Treatment, and Prevention of Cancer-Associated Venous Thromboembolism. **2014**, 542-561.e7

79 Multiple Myeloma and Related Disorders. **2014**, 1991-2017.e7

1

78 Multiple Myeloma. **2015**, 203-218

77 Endokrines System und Immunmodulation. **2015**, 675-747

76 Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications. **2015**, 187-235

75 Cardiovascular Emergencies. **2016**, 179-190

74 Bleeding and Thrombosis in Cancer Patients. **2016**, 235-242

73 Multiple Myeloma. **2017**,

72 Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma?. **2017**, 21, 37-46

2

71 Multiples Myelom beim alten und geriatrischen Patienten. **2018**, 1-10

70	Multiples Myelom beim alten und geriatrischen Patienten. 2018 , 261-270		
69	Endokrines System und Immunmodulation. 2018 , 721-796		
68	CARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: CLINICAL FEATURES, DIAGNOSIS, TREATMENT, PREVENTION (PART II). 2018 , 23, 43-49		
67	Validation of the IMPEDE VTE Score for Prediction of Venous Thromboembolism in Multiple Myeloma: A Retrospective Cohort Study.		
66	Cancer et thrombose. 2020 , 334-340.e1		
65	Front line treatment of elderly multiple myeloma in the era of novel agents. 2009 , 3, 99-109		5
64	Novel treatment paradigm for elderly patients with multiple myeloma. 2011 , 1, 190-204		8
63	Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges. 2014 , 8, 12-8		3
62	Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications. 2013 , 4, 37-46		1
61	[Clinical analysis of thromboembolism associated with lenalidomide-based regimens for multiple myeloma patients]. 2016 , 37, 245-7		
60	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
59	Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab □ case report. 2021 , 8, 136-140		
58	NCCN Guidelines□ Insights: Multiple Myeloma, Version 3.2022.. 2022 , 20, 8-19		7
57	Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.. 2022 , 6, e12634		2
56	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma.. 2022 ,		1
55	Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.. 2022 , 20, 91-95		1
54	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes.. 2022 ,		0
53	Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.. 2022 ,		

52	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.. 2021 , JCO2101935			13
51	Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.. 2022 , 5, 214-228			1
50	Cardiovascular-specific mortality among multiple myeloma patients: a population-based study.. 2022 , 13, 20406207221086755			1
49	Endokrines System und Immunmodulation. 2022 , 799-885			
48	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. 2022 , 3, 188-203			
47	Current Approaches to Management of Newly Diagnosed Multiple Myeloma.. <i>American Journal of Hematology</i> , 2022 ,	7.1		2
46	Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study.. 2022 , 213, 27-29			1
45	Cancer thrombosis: Narrative review. 2020 , 3, 501			1
44	Immune checkpoint inhibitors and venous thromboembolism: an analysis of the WHO pharmacovigilance database.. 2022 ,			0
43	Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases. 2022 , 17, 134-140			
42	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. 155-183			
41	Incidence, causes, and timing of peripheral intravenous catheter failure related to insertion timing in the treatment cycle in patients with hematological malignancies: A prospective descriptive study.. 2022 , e12484			2
40	Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target Specific Nanotherapies in Disease Models. 2022 , 17,			
39	Metformin inhibits multiple myeloma serum-induced endothelial cell thrombosis by down-regulating miR-532.. 2022 ,			2
38	Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2720	5.1		0
37	Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM/DFCI 2009 cohort.. <i>Journal of Thrombosis and Haemostasis</i> , 2022 ,	15.4		0
36	Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management.. <i>American Journal of Hematology</i> , 2022 ,	7.1		12
35	Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro-prospective observational study. <i>European Journal of Haematology</i> ,	3.8		0

34	Thromboprophylaxis in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1-9	1.9	1
33	Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka. <i>JCO Global Oncology</i> , 2022,	3-7	
32	Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score. <i>Blood</i> ,	2.2	0
31	What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. <i>Targeted Oncology</i> ,	5	0
30	Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. <i>British Journal of Haematology</i> ,	4-5	0
29	Myeloma and Leukemia. 2023, 503-528		
28	Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. <i>Haematologica</i> ,	6.6	0
27	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).		4
26	Evidence-based medical treatment of POEMS syndrome.		0
25	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).		39
24	Development and Validation of a New Risk Assessment Model for Immunomodulatory Drug-Associated Venous Thrombosis Among Chinese Patients with Multiple Myeloma.		0
23	Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma. 2022, 3, 518-526		0
22	Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.		0
21	Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.		0
20	Vascular thrombotic events in the era of modern myeloma therapy.		0
19	Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.		0
18	Plasma Cell Disorders. 1-30		0
17	Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma.		0

- 16 From mechanism to resistance [Changes in the use of dexamethasone in the treatment of multiple myeloma. 1-9 ○
- 15 An MDM2 degrader for treatment of acute leukemias. ○
- 14 Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients' and Clinicians' Awareness. **2022**, 12, 1594 ○
- 13 Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience. **2022**, 14, 5640 ○
- 12 Oral Therapies for Multiple Myeloma. **2022**, 18, 139 ○
- 11 Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. **2022**, 14, 6216 ○
- 10 VTE prophylaxis in multiple myeloma. **2022**, 140, 2413-2414 ○
- 9 When Two Maladies Meet: Disease Burden and Pathophysiology of Stroke in Cancer. **2022**, 23, 15769 ○
- 8 Bleeding risk in patients with multiple myeloma treated for venous thromboembolism: a MarketScan analysis. **2023**, 7, 100024 ○
- 7 Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma. ○
- 6 External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. 1
- 5 First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. **2023**, 23, 340-354 ○
- 4 Treatment and Disease-related Complications in Multiple Myeloma. ○
- 3 Overview of venous thromboembolism (VTE) in patients with haematological malignancy. **2023**, 7, 52-58 ○
- 2 Nursing management of treatment-related venous thromboembolism in patients with multiple myeloma. 10, ○
- 1 Thrombosis events in Chinese patients with newly diagnosed multiple myeloma. ○